Abstract:OBJECTIVE To evaluate retinoblastoma regression patterns following chemo reduction and adjuvant therapy. METHODS Retrospective case series. 122 tumors of 47 eyes of 37 patients following chemo reduction and adjuvant therapy between January 2005 and June 2009 in the Eye & ENT hospital of Fudan University. Twenty-seven patients are male, and 10 patients are female. The average age was 22 months. The combined therapy included chemo reduction using vincristine, etoposide, and carboplatin (VEC) combined with local cryotherapy and/or transpupillary thermotherapy (TTT). The average follow-up duration was 32 months ranging from 12 to 60 months. Regression patterns included type 0 (no remnant), type 1 (calcified remnant), type 2 (noncalcified remnant), type 3 (partially calcified remnant), and type 4 (flat scar). Wilcoxon rank sum test was used to test the difference of tumor number between the patients with family history and those without family history. Chi-square test was used to test the difference between the tumor thickness, tumor location and regression patterns. Multivariate logistic regression analysis was used to test the correlation between the regression patterns and age, sex, tumor thickness, tumor location and family history. Statistical significance was assigned at P < 0.05. RESULTS Forty-seven eyes according to the International Intraocular Retinoblastoma Classification, 20 eyes (42.6%) were group A, 13 eyes (27.6%) group B, 6 eyes (12.8%) group C, 8 eyes (17.0%) group D. Of 122 tumors, the average number of tumors per eye was 2.6. Retinoblastoma regressions were type 0 (n = 3), type 1 (n = 15), type 2 (n = 8), type 3 (n = 25), and type 4 (n = 71). Tumor thickness and tumor location were related to regression patterns. Tumors with an initial thickness of 2 mm or less regressed most often to type 4, and those thicker than 8 mm regressed to type 1 or type 3. Tumors with greater distance from the foveola regressed most often to type 4. The factors predictive of regression pattern type 1 included tumor thickness larger than 8 mm (Z = 3.02, P = 0.003). The factors predictive of regression pattern type 3 included older age, tumor thickness larger than 8 mm and location not in the equator to ora serrata region (Z = 3.98, 2.23, 3.60; P = 0.000, 0.025, 0.000). The factors predictive of regression pattern type 4 included familial hereditary pattern, tumor thickness smaller than 2 mm and location in the equator to ora serrata region. (Z = 4.37, 3.42, 2.42; P = 0.000, 0.000, 0.021). 12 tumors recurred, 9 tumors were type 3 and 3 tumors were type 4. 8 eyes developed 15 new tumors. 5 patients developed new tumors were all younger patients and had familial hereditary history. The average period of recurrence of main tumors and development of new tumors was six months after the end of chemo reduction. CONCLUSIONS Following chemo reduction, type 3 and type 4 regression patterns were most common. Smaller tumors were usually seen in type 4, and bigger tumors were usually seen in type 1 or type 3. Tumor recurrence was usually found following regression pattern type 3 or type 4. Younger patients and patients with familial hereditary history trend to develop new tumors. Patients accept chemo reduction and adjuvant therapy need close follow-up.

[Clinical Therapeutic Efficiency of Chemoreduction and Local Therapy for Children with Retinoblastoma].

Clinical efficacy and prognostic factors of chemoreduction combined with topical treatment for advanced intraocular retinoblastoma

Effectiveness and safety of chemoreduction by VEC for intraocular retinoblastoma

[Results of combined chemotherapy and local ophtalmic therapy for intraocular retinoblastoma]

Clinical Characteristics and Treatment Outcome of Children with Intraocular Retinoblastoma: A Report from A Chinese Cooperative Group

Conservative treatments of intraocular retinoblastoma

Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre

Outcomes of Combined Modality Therapy of Retinoblastoma

Combined Systemic Chemotherapy with Periocular Carboplatin Injection for Orbital Involvement of Retinoblastoma

The cinical analysis of 317 cases of retinoblastoma

Retinoblastoma Regression Patterns and Results Following Chemoreduction and Adjuvant Therapy

Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARET0331): A report from the Children's Oncology Group

Eye-Preserving Therapies for Advanced Retinoblastoma

Prospective phase II study of children affected by bilateral intraocular retinoblastoma with macular involvement of both eyes or in the only preserved eye. Macular tumor control, eye preservation rate, and visual outcome

[The Efficacy of Large Spot Indirect Ophthalmoscopy Laser Alone or Combined with Systemic Chemotherapy in Retinoblastoma Therapy].

The Clinical Analysis of Conservative Treatments for Retinoblastoma

[Retinoblastoma regression patterns and results following chemo reduction and adjuvant therapy].

[Clinicopathologic Features of Retinoblastoma and Expression of VEGF and Ki-67 after Comprehensive Treatment].

Combined Intra-Arterial Chemotherapy and Intravitreal Melphalan for the Treatment of Advanced Unilateral Retinoblastoma.

Clinical treatment and prognostic observation for different pathological infiltrations in 537 patients with unilateral retinoblastoma.

Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma